Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Leukemia. 2012 Jun 18;27(1):226–232. doi: 10.1038/leu.2012.160

Figure 5.

Figure 5

IRS ratios from the start of therapy for all patients (a) or from the onset of CR for the subset of patients who attained CR (b). OS, adjusted for the expected survival of the US population, stratified by gender and age at registration, was calculated over 1-year intervals. With the transitions from TT1 to TT2 and TT3 trials, IRS ratios were successively higher from the outset, and improvements toward normal occurred earlier, whether examined for all patients or for those who attained CR. Black, TT1; blue, TT2 − Thal; red, TT2 + Thal; and green, TT3. (95% Confidence intervals provided in Supplementary Tables 2A–B).